Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

660 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease.
Koury MJ, Agarwal R, Chertow GM, Eckardt KU, Fishbane S, Ganz T, Haase VH, Hanudel MR, Parfrey PS, Pergola PE, Roy-Chaudhury P, Tumlin JA, Anders R, Farag YMK, Luo W, Minga T, Solinsky C, Vargo DL, Winkelmayer WC. Koury MJ, et al. Among authors: eckardt ku. Am J Hematol. 2022 Sep;97(9):1178-1188. doi: 10.1002/ajh.26644. Epub 2022 Jul 15. Am J Hematol. 2022. PMID: 35751858 Free PMC article.
Pathophysiology of renal anemia.
Eckardt KU. Eckardt KU. Clin Nephrol. 2000 Feb;53(1 Suppl):S2-8. Clin Nephrol. 2000. PMID: 10746799 Review.
Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Solomon SD, et al. Among authors: eckardt ku. N Engl J Med. 2010 Sep 16;363(12):1146-55. doi: 10.1056/NEJMoa1005109. N Engl J Med. 2010. PMID: 20843249 Free article. Clinical Trial.
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT).
McMurray JJ, Uno H, Jarolim P, Desai AS, de Zeeuw D, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, Parfrey P, Parving HH, Toto RM, Solomon SD, Pfeffer MA. McMurray JJ, et al. Among authors: eckardt ku. Am Heart J. 2011 Oct;162(4):748-755.e3. doi: 10.1016/j.ahj.2011.07.016. Am Heart J. 2011. PMID: 21982669 Clinical Trial.
C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
Mc Causland FR, Claggett B, Burdmann EA, Eckardt KU, Kewalramani R, Levey AS, McMurray JJ, Parfrey P, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA. Mc Causland FR, et al. Among authors: eckardt ku. Am J Kidney Dis. 2016 Dec;68(6):873-881. doi: 10.1053/j.ajkd.2016.07.022. Epub 2016 Sep 16. Am J Kidney Dis. 2016. PMID: 27646425 Free PMC article. Clinical Trial.
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial.
Mc Causland FR, Claggett B, Pfeffer MA, Burdmann EA, Eckardt KU, Levey AS, McMurray JJV, Remuzzi G, Singh AK, Solomon SD, Toto RD, Parfrey P. Mc Causland FR, et al. Among authors: eckardt ku. Am J Nephrol. 2017;46(6):488-497. doi: 10.1159/000485326. Epub 2017 Dec 14. Am J Nephrol. 2017. PMID: 29241199 Free PMC article. Clinical Trial.
Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Eckardt KU, Bansal N, Coresh J, Evans M, Grams ME, Herzog CA, James MT, Heerspink HJL, Pollock CA, Stevens PE, Tamura MK, Tonelli MA, Wheeler DC, Winkelmayer WC, Cheung M, Hemmelgarn BR; Conference Participants. Eckardt KU, et al. Kidney Int. 2018 Jun;93(6):1281-1292. doi: 10.1016/j.kint.2018.02.006. Epub 2018 Apr 12. Kidney Int. 2018. PMID: 29656903 Free PMC article.
660 results